In-silico study for the identification of potential destabilizers between the spike protein of SARS-CoV-2 and human ACE-2

In-silico study for the identification of potential destabilizers between the spike protein of SARS-CoV-2 and human ACE-2

The emergence of the new SARS-CoV-2 virus, which causes the disease known as COVID-19, has generated a pandemic that has plunged the world into a health crisis. The infection process is triggered by the direct binding of the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 to the...

Descripció completa

Dades bibliogràfiques
Autors principals:	Jeffry Medina-Barandica, Neyder Contreras-Puentes, Arnulfo Tarón-Dunoyer, Marlene Durán-Lengua, Antistio Alviz-Amador
Format:	Article
Idioma:	English
Publicat:	Elsevier 2023-01-01
Col·lecció:	Informatics in Medicine Unlocked
Matèries:	COVID-19 SARS-CoV-2 RBD ACE2 Molecular docking Molecular dynamics
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2352914823001223

Ítems similars

Evaluating the Spike–hACE2 interactions in the wild type and variants of concern of SARS -CoV-2 at different temperatures
per: Nabanita Mandal, et al.
Publicat: (2024-01-01)

Molecular docking study and mapping the binding site of some antiviral nanobodies against receptor binding domain (RBD) of SARS-COV 2
per: zahra pahlavan, et al.
Publicat: (2021-06-01)

In silico study of local anesthetics analogues on sodium channel Nav 1.7 a pharmacological target on inflamed dental pulp
per: Isabella Manzur-Villalobos, et al.
Publicat: (2022-01-01)

Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
per: Abdullah Hoter, et al.
Publicat: (2022-05-01)

A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS‐CoV‐2 Spike‐Mediated Viral Invasion
per: Mengdan Wu, et al.
Publicat: (2023-10-01)

Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
per: Acharya Balkrishna, et al.
Publicat: (2025-02-01)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
per: Ming-Feng He, et al.
Publicat: (2022-10-01)

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein
per: Lingbing Zhang, et al.
Publicat: (2022-06-01)

Structural basis of increased binding affinities of spikes from SARS-CoV-2 Omicron variants to rabbit and hare ACE2s reveals the expanding host tendency
per: Kaiyuan Shi, et al.
Publicat: (2024-02-01)

Exploring the Interaction between Vancomycin/Teicoplanin and Receptor Binding Domain (RBD) of SARS-CoV-2
per: Wen-Tao Tao, et al.
Publicat: (2021-01-01)

АНАЛИЗ ВЛИЯНИЯ МУТАЦИЙ НА АФФИННОСТЬ СВЯЗЫВАНИЯ В КОМПЛЕКСАХ ACE2 И RBD S-БЕЛКА КОРОНАВИРУСОВ
per: Богданова Е.А., et al.
Publicat: (2023-11-01)

Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor
per: Arun Bahadur Gurung, et al.
Publicat: (2022-02-01)

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
per: Arun Bahadur Gurung, et al.
Publicat: (2021-02-01)

Xeno-Nucleic Acid (XNA) 2’-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding
per: Irani Alves Ferreira-Bravo, et al.
Publicat: (2021-10-01)

Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism
per: Riadh Badraoui, et al.
Publicat: (2021-01-01)

A Pathway Model to Understand the Evolution of Spike Protein Binding to ACE2 in SARS-CoV-2 Variants
per: Ludovico Pipitò, et al.
Publicat: (2022-10-01)

Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Different Coronavirus Spike Protein and ACE2
per: Israa Mohamed Shamkh, et al.
Publicat: (2021-06-01)

Structural analysis of a simplified model reproducing SARS-CoV-2 S RBD/ACE2 binding site
per: Michela Buonocore, et al.
Publicat: (2022-11-01)

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
per: Valentin A. Semenov, et al.
Publicat: (2022-12-01)

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
per: Debashree Chatterjee, et al.
Publicat: (2022-01-01)

Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
per: Deepa Raghu, et al.
Publicat: (2022-02-01)

A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro
per: Xiaolong Yang, et al.
Publicat: (2021-06-01)

Investigation of some plant stilbenoids and their fragments for the identification of inhibitors of SARS-CoV-2 viral spike/ACE2 protein binding
per: Cyril T. Namba-Nzanguim, et al.
Publicat: (2024-06-01)

Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach
per: Mayra Avelar, et al.
Publicat: (2023-03-01)

Rapid screening of SARS-CoV-2 inhibitors via ratiometric fluorescence of RBD–ACE2 complexes in living cells by competitive binding
per: Lu Miao, et al.
Publicat: (2022-09-01)

Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2
per: Ting Wang, et al.
Publicat: (2022-09-01)

Andrographolide binds to spike glycoprotein and RNA-dependent RNA polymerase (NSP12) of SARS-CoV-2 by in silico approach: a probable molecule in the development of anti-coronaviral drug
per: Lokanathan Srikanth, et al.
Publicat: (2021-07-01)

Computational design of medicinal compounds to inhibit RBD-hACE2 interaction in the Omicron variant: unveiling a vulnerable target site
per: Muhammad Shahab, et al.
Publicat: (2023-01-01)

A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2)
per: Paolo Coghi, et al.
Publicat: (2021-09-01)

<i>In silico</i> screening of chalcones and their derivatives as potential inhibitors of spike proteins and ACE2 enzymes for SARS-CoV-2 treatment
per: Thi Thu Hang Ta, et al.
Publicat: (2022-06-01)

Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition
per: Lorenzo Di Rienzo, et al.
Publicat: (2021-01-01)

Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2
per: Yixin Xie, et al.
Publicat: (2020-12-01)

Design and selection of peptides to block the SARS-CoV-2 receptor binding domain by molecular docking
per: Kendra Ramirez-Acosta, et al.
Publicat: (2022-07-01)

Studying the Effect of Glycosylation towards SARS-CoV-2 Spike RBD and ACE2 Interaction by Native Mass Spectrometry
per: LUO Yu-xiang;HUANG Jing;LI Hui-lin
Publicat: (2022-11-01)

Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model
per: Balkrishna A, et al.
Publicat: (2021-03-01)

Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor
per: Ahmed A. Al-Karmalawy, et al.
Publicat: (2021-05-01)

Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq
per: Ali A. Dawood, et al.
Publicat: (2022-07-01)

A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2
per: Xiaoning Wang, et al.
Publicat: (2021-02-01)

Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2
per: Ariana Ghez Farrell, et al.
Publicat: (2022-09-01)

Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2
per: Xi Chen, et al.
Publicat: (2022-08-01)